Limited Evidence Links Pioglitazone to Bladder Cancer

This article originally appeared here.
Share this content:
Limited Evidence Links Pioglitazone to Bladder Cancer
Limited Evidence Links Pioglitazone to Bladder Cancer

(HealthDay News) – Limited evidence supports an increased risk of bladder cancer in adults with type 2 diabetes treated with thiazolidinediones, specifically pioglitazone, according to a review and meta-analysis published online July 3 in CMAJ, the journal of the Canadian Medical Association.

Isabelle N. Colmers, of the University of Alberta in Edmonton, Canada, and colleagues performed a systematic review and meta-analysis of 4 randomized controlled trials (RCTs), 5 cohort studies, and 1 case-control study. The studies evaluated the risk of bladder cancer in adults with type 2 diabetes who were treated with thiazolidinediones, including pioglitazone or rosiglitazone.

The researchers identified 3,643 newly diagnosed cases of bladder cancer among the 2,657,365 patients who participated in the studies, for an overall incidence of 53.1 per 100,000 person-years. The cohort studies showed an increased risk of bladder cancer with thiazolidinedione treatment (pooled risk ratio [RR], 1.15), specifically pioglitazone (pooled RR, 1.22). However, no significant correlation was observed with bladder cancer in the 1 RCT that assessed pioglitazone (RR, 2.63; 95% confidence interval [CI], 0.91 to 6.13) or the 2 RCTs that assessed rosiglitazone (pooled RR, 0.87; 95% CI, 0.34 to 2.23).

"Although the absolute risk of bladder cancer associated with pioglitazone was small, other evidence-based treatments for type 2 diabetes may be equally effective and do not carry a risk of cancer," the authors write. "This study quantifies the association between pioglitazone use and bladder cancer and may help inform decisions around safer use of pioglitazone in individuals with type 2 diabetes."

Full Text

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs